Drug Profile
Faropenem medoxomil
Alternative Names: A0026; BAY 56-6854; Faropenem daloxate; SUN 208; SUN A0026Latest Information Update: 04 Aug 2011
Price :
$50
*
At a glance
- Originator Asubio Pharma
- Developer Cardiovascular Systems; Replidyne
- Class Antibacterials; Beta-lactams; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Acute exacerbations of chronic bronchitis; Acute sinusitis; Bacterial infections; Community-acquired pneumonia
- No development reported Anthrax; Otitis media; Pharyngitis; Tonsillitis
- Discontinued Skin and soft tissue infections; Urinary tract infections
Most Recent Events
- 26 Feb 2009 Replidyne is now called Cardiovascular Systems, Inc.
- 28 Oct 2008 Efficacy and safety data from a phase III trial in Acute exacerbations of chronic bronchitis presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Annual Meeting of the Infectious Diseases Society of America (ICAAC/IDSA-2008)
- 24 Apr 2008 Suspended - Phase-III for Acute exacerbations of chronic bronchitis in USA (PO)